MiniSeqTM Sequencing System Makes Illumina NGS Accessible for
Infinium® XT Enables Highest Throughput Genotyping to Date
Illumina Previews Project Firefly: A Breakthrough Semiconductor-Based Sequencing System
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160111006398/en/
“Illumina has a history of breaking down barriers in genomics by making sequencing and genotyping easier to perform and less expensive. The MiniSeq Sequencing System and Infinium XT technologies build on this legacy and will enable researchers and applied practitioners to unlock the power of the genome like never before,” said
The new MiniSeq System makes Illumina’s trusted sequencing technology accessible to all laboratories interested in performing targeted sequencing. With push-button operation, the flexible benchtop sequencer enables a broad range of DNA and RNA sequencing applications, from examining single genes to entire pathways, in a single run. Priced at
The research-use only MiniSeq System is designed and being commercialized as part of a complete sequencing solution that enables both experienced and new-to-NGS researchers to get results quickly with an easy-to-use library-to-results workflow and onboard data analysis for numerous assays. The sequencer is also able to stream sequencing data to BaseSpace®, Illumina’s cloud and onsite genomics computing environment. Compatible with a full suite of
The MiniSeq System will begin shipping early in the first quarter of 2016. For more information, visit www.illumina.com/miniseq.
Infinium XT builds on the success of the Infinium product family offering Illumina’s highest throughput array format to date. The 96-sample BeadChip offers laboratories the ability to perform genotyping on larger numbers of samples, testing up to 50,000 markers per sample and enabling laboratories to scale up to one million samples or more per year. This solution is ideally suited for agrigenomics applications, which require low plexity assays, especially for parentage, meat traceability, and genomic selection. This product will also enable human applications, particularly for biobanks and personalized medicine initiatives with large scale targeted genotyping.
Infinium XT will begin shipping in the third quarter of 2016.
The new system will be superior to competing semiconductor-based sequencing systems with a raw error rate of less than one percent, data quality comparable to that of a HiSeq XTM Sequencing System. With output of approximately 1.2G per run, the platform will be ideal for numerous markets including academic research, oncology, infectious disease, inherited disease, and reproductive health.
This release contains forward looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch, shipping, or commercialization dates for new products; performance characteristics for new products; and pricing for new products. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; and the other factors detailed in our filings with the
David Robertson, Europe, Middle East and Africa
+44 1223 824909